About this Research Topic
Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET)/ Computed Tomography (CT) is a major tool for both primary and secondary staging of prostate cancer. Despite not strictly being in the guidelines for primary staging, it has already replaced the conventional techniques in many centers especially in intermediate and high risk patients. Its role in identifying rising prostate specific antigen (PSA) following treatments with curative intent and in monitoring of patients with advanced disease following different treatment modalities on the other hand is already recognized, and is also featured in clinical guidelines. Moreover PSMA based theranostics using Lutetium or Actinium seems to be a major component in the sequential treatment of the advanced stage patients. More and more research efforts aim to establish a role for theranostics at an earlier stage of the disease.
With this collection of research articles we wish to cover topics that are currently drawing attention regarding the use of PSMA PET CT in different stages of prostate cancer with different purposes. These papers may be original articles or reviews dealing with specific questions in primary staging or secondary staging of the disease, together with the use of Lu177 or Actinium125 as PSMA based treatment modalities during the relatively long advanced disease stage.
The special issue aims to address both primary and secondary staging in prostate cancer cases, but also the possibilities of theranostics in these cases. Secondary staging is actually much more frequently addressed in the literature but the missing part is sequential PSMA scans in response to different therapeutic steps during castration naïve metastatic, castration resistant nonmetastatic, and finally castration resistant metastatic cancers. Similarly persistent PSA situations in patients staged primarily with PSMA PET CT prior to radical prostatectomy is an interesting and uncharted area. The role of PSMA in active surveillance of patients is interesting but difficult to study because of the reimbursement issues in many countries. Similarly, diagnostic comparison of whole body MRI and PSMA is very timely to study. PSMA guided salvage therapy including radiation treatment following radical prostatectomy and/or salvage lymphadenectomy are other important topics to cover. Finally results with Lutetium and Actinium in the treatment of castration resistant metastatic prostate cancer defining not only the role but also the timing are of utmost importance . This topics can be covered either as original papers (active surveillance, sequential PSMA , persistent PSA postprostatectomy or post-radiation PSMA etc.) or a review paper (PSMA technology in general, PSMA guided treatment, ,theranostics)
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
With this collection of research articles we wish to cover topics that are currently drawing attention regarding the use of PSMA PET CT in different stages of prostate cancer with different purposes. These papers may be original articles or reviews dealing with specific questions in primary staging or secondary staging of the disease, together with the use of Lu177 or Actinium125 as PSMA based treatment modalities during the relatively long advanced disease stage.
The special issue aims to address both primary and secondary staging in prostate cancer cases, but also the possibilities of theranostics in these cases. Secondary staging is actually much more frequently addressed in the literature but the missing part is sequential PSMA scans in response to different therapeutic steps during castration naïve metastatic, castration resistant nonmetastatic, and finally castration resistant metastatic cancers. Similarly persistent PSA situations in patients staged primarily with PSMA PET CT prior to radical prostatectomy is an interesting and uncharted area. The role of PSMA in active surveillance of patients is interesting but difficult to study because of the reimbursement issues in many countries. Similarly, diagnostic comparison of whole body MRI and PSMA is very timely to study. PSMA guided salvage therapy including radiation treatment following radical prostatectomy and/or salvage lymphadenectomy are other important topics to cover. Finally results with Lutetium and Actinium in the treatment of castration resistant metastatic prostate cancer defining not only the role but also the timing are of utmost importance . This topics can be covered either as original papers (active surveillance, sequential PSMA , persistent PSA postprostatectomy or post-radiation PSMA etc.) or a review paper (PSMA technology in general, PSMA guided treatment, ,theranostics)
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Keywords: prostate cancer staging, PSMA PET CT, theranostics, Lu177, advanced prostate cancer, high risk prostate cancer, salvage lymphadenectomy
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
